|
(V1298) |
Investigation of S100A4 as a target of the E3 ubiquitin ligase Asb2β and its functional effect on engineered heart tissue |
| |
|
S. Braumann, F. W. Friedrich, T. Thottakara, S. Reischmann, P. Lutz, T. Eschenhagen, C. Moog-Lutz, L. Carrier (Hamburg; Toulouse, FR) |
|
|
Diskussion |
|
(V1299) |
Inhibition of Prolyl Hydroxylase as therapeutic target for HIF-mediated SDF-1 activation and stem cell homing in the ischemic heart |
| |
|
S. Ghadge, T. V. Pham, M. Doppelhammer, W.-M. Franz, M.-M. Zaruba (Innsbruck, AT; München) |
|
|
Diskussion |
|
(V1300) |
Repeat administration of a cyclic peptide CXCR4 antagonist decreases infarct scar size and improves systolic function in mice and pigs with reperfused acute myocardial infarction |
| |
|
Y. Wang, L. C. Napp, H. Frank, J. Bauersachs, G. Heusch, E. Chevalier, K. Dembowsky, M. Gyöngyösi, K. C. Wollert (Hannover, Essen; Allschwil, CH; Wien, AT) |
|
|
Diskussion |
|
(V1301) |
Entwicklung eines Gentherapieansatzes zur Behandlung der Kardiomyopathie bei Desminopathien |
| |
|
M. Heckmann, R. Bauer, K. H. Strucksberg, R. Schröder, H. A. Katus, O. J. Müller (Heidelberg, Erlangen) |
|
|
Diskussion |
|
(V1302) |
Effectiveness of Cardiac Gene Therapy with VEGF-B167 in a Pre-clinical Model of Dilated Cardiomyopathy |
| |
|
F. Woitek, L. Zentilin, J. Powers, M. Hurst, A. Kulczycki, A. Lam, N. Hoffmann, N. Ring, M. Madesh, A. Sabri, S. R. Houser, M. Giacca, F. Recchia (Leipzig; Trieste, IT; Philadelphia, US) |
|
|
Diskussion |
|
(V1303) |
Myocardial HDAC4-NT Gene Therapy Protects Adverse Cardiac Remodelling |
| |
|
Z. H. Jebessa, L. H. Lehmann, H. A. Katus, J. Backs (Heidelberg) |
|
|
Diskussion |